Changing respiratory health forever
RESPINOR is developing a novel, non-invasive, ultrasound-based medical device for continuous diaphragm monitoring, the main breathing muscle. RESPINOR’s technology is the winner of Horizon 2020 funding both in phase I and II. The company has successfully completed clinical feasibility studies in Europe for the first target segment mechanical ventilation (MV) with technical proof of principle and proof of concept confirmed. Our technology has a broad range of potential benefits and represents a technology platform for applications in critical care and other areas of respiratory medicine.
RESPINOR has started the last phase of the clinical program, DE-RISK-WF study in Europe, with DXT before regulatory submission (EU and USA)
First patient enrolled in RESPINOR’s mechanical ventilation WEAN-US study at Hospitalier Pitié-Salpêtrière in Paris, France.
For patients with chronic respiratory diseases as well as in critical settings, there is a clear need for a non-invasive ultrasound tool to better characterize diaphragm muscle weakness.EU Eurostars evaluator comment
RESPINOR develops innovative products for monitoring of respiratory function. RESPINOR is dedicated to provide uncompromised quality products that are safe and cost-effective to health care systems.
We understand that listening to customer needs and meeting market needs are key to continued product improvement.
RESPINOR is committed to maintaining an effective quality management system compliant with all applicable regulations in countries where our products are developed, manufactured and sold.